This article was originally published in The Tan Sheet
More than 2,600 subjects enrolled in NIH-sponsored Vitamin Intervention for Stroke Prevention Study, with recruitment expected to continue through 2001, to reach 3,600-patient target, according to an abstract presented at the 26th International Stroke Conference in Fort Lauderdale, Fla. Feb. 14-16. VISP is a double-blind, randomized, controlled trial with centers in U.S., Canada and Scotland; subjects receive either low or high doses of folic acid, vitamins B6 and B12. Primary outcome is recurrent cerebral infarction. Separately, enrollment will continue until 2003 for 8,000-patient VITATOPS study examining whether B vitamins reduce combined incidence of recurrent vascular events and vascular death in patients with recent stroke or TIA. Study encompasses centers in Australia, New Zealand, Italy, U.K
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC